ArticleScientific reports2022

In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia.

Suliman A Alsagaby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.